PRIMARY SCLEROSING CHOLANGITIS
Clinical trials for PRIMARY SCLEROSING CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY SCLEROSING CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an old antibiotic tame a rare liver disease?
Disease control TerminatedThis study tested whether oral vancomycin, an antibiotic, can safely improve liver health in adults with primary sclerosing cholangitis (PSC), a rare disease that damages bile ducts. About 102 participants were planned to receive vancomycin or a placebo for up to 24 months. The m…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2, PHASE3 • Sponsor: Elizabeth Carey • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug A3907 tested for rare liver disease PSC
Disease control TerminatedThis study tested a drug called A3907 in 18 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The main goal was to see if the drug is safe and tolerable. The study was stopped early, so results are limited.
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 13, 2026 16:03 UTC